

51 1647
CRW \$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yi WANG et al.

Serial No. 09/528,225

Filed: March 21, 2000



:
:
:
:
Group Art Unit: 1647

:
Examiner: Christine J. Saoud

For: CHIMERIC PROTEINS FOR DIAGNOSIS AND TREATMENT DIABETES

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the document listed on the attached form PTO-1449. It is respectfully requested that the document be expressly considered during the prosecution of this application, and that the document be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

In accordance with 37 C.F.R. § 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The referenced patent application was allowed on February 17, 2005. In the Notice of Allowance, the Examiner noted, with respect to the IDS filed November 22, 2004, that there was one citation on the IDS without a copy provided (Pereyra et al.) and therefore, this reference was


not considered. Applicants are providing herewith a copy of the Pereyra reference for the Examiner's consideration prior to payment of the issue fee.

Applicant petitions for consideration of the enclosed documents by the Examiner. The petition fee of \$180.00 pursuant to 37 CFR § 1.17(p) is attached. No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement. The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

The fee of \$180.00 pursuant to 37 CFR § 1.17(p) is attached. The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 08-0219.

Respectfully submitted,

WILMER CUTLER PICKERING HALE AND DORR LLP

A large, stylized handwritten signature in black ink, appearing to read 'H. Wixon', is written over the printed name and registration number.

Henry N. Wixon
Registration No. 32,073

1455 Pennsylvania Avenue, NW
Washington, DC 20004
TEL 202.942.8400 HNW/BL/mgm
FAX 202.942.8484
Date: 6 MAY 2005

3